GENTIAN DIAGNOSTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36 NOK | 0.00% |
|
-1.64% | -13.25% |
| Sales 2024 * | 171M 15.42M | Sales 2025 * | 203M 18.34M | Capitalization | 555M 50.2M |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -995K | Net income 2025 * | -6M -542K | EV / Sales 2024 * | 3.06 x |
| Net cash position 2024 * | 34M 3.07M | Net cash position 2025 * | 15M 1.36M | EV / Sales 2025 * | 2.66 x |
| P/E ratio 2024 * |
-48.1
x | P/E ratio 2025 * |
-84.6
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gentian Diagnostics
More press releases
| 1 week | -1.64% | ||
| Current month | -7.22% | ||
| 1 month | -5.51% | ||
| 3 months | -14.08% | ||
| 6 months | -13.25% | ||
| Current year | -13.25% |
1 week
34.80
37.00
1 month
34.8040.30
Current year
34.8044.00
1 year
34.8049.90
3 years
34.8086.00
5 years
34.8089.00
10 years
22.0089.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hilja Ibert
CEO | Chief Executive Officer | - | 18-07-15 |
Njaal Kind
DFI | Director of Finance/CFO | 52 | 18-01-01 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Settevik
CHM | Chairman | 64 | - |
Fredrik Thoresen
BRD | Director/Board Member | 44 | - |
| Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 36 | 0.00% | 4,167 |
| 24-04-17 | 36 | 0.00% | 4,932 |
| 24-04-16 | 36 | +0.56% | 1,612 |
| 24-04-15 | 35.8 | -1.10% | 8,704 |
| 24-04-12 | 36.2 | -1.09% | 5,792 |
Real-time Oslo Bors, April 18, 2024 at 10:45 am EDT
More quotes
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company's product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Calendar
2024-04-28
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
36
NOK
Average target price
54
NOK
Spread / Average Target
+50.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.25% | 50.38M | |
| -1.59% | 12.47B | |
| -17.62% | 6.99B | |
| -3.93% | 5.1B | |
| -6.68% | 4.27B | |
| +0.53% | 4.27B | |
| -48.27% | 3.45B | |
| +7.09% | 2.61B | |
| -13.71% | 2.08B | |
| -3.40% | 1.67B |
- Stock Market
- Equities
- GENT Stock
